A phase II multicenter, open-label study of YM155 in refractory diffuse large B-cell lymphoma (DLBCL) subjects
Phase of Trial: Phase II
Latest Information Update: 25 May 2016
At a glance
- Drugs Sepantronium bromide (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 12 May 2009 Additional trial locations identified as reported by ClinicalTrials.gov.
- 12 May 2009 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 23 Oct 2008 Status changed from recruiting to suspended, based on information from ClinicalTrials.gov.